[HTML][HTML] Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ (1-42)

J Everett, J Brooks, F Lermyte, PB O'Connor…�- Scientific Reports, 2020 - nature.com
Scientific Reports, 2020nature.com
Atypical low-oxidation-state iron phases in Alzheimer's disease (AD) pathology are
implicated in disease pathogenesis, as they may promote elevated redox activity and
convey toxicity. However, the origin of low-oxidation-state iron and the pathways responsible
for its formation and evolution remain unresolved. Here we investigate the interaction of the
AD peptide β-amyloid (Aβ) with the iron storage protein ferritin, to establish whether
interactions between these two species are a potential source of low-oxidation-state iron in�…
Abstract
Atypical low-oxidation-state iron phases in Alzheimer’s disease (AD) pathology are implicated in disease pathogenesis, as they may promote elevated redox activity and convey toxicity. However, the origin of low-oxidation-state iron and the pathways responsible for its formation and evolution remain unresolved. Here we investigate the interaction of the AD peptide β-amyloid (Aβ) with the iron storage protein ferritin, to establish whether interactions between these two species are a potential source of low-oxidation-state iron in AD. Using X-ray spectromicroscopy and electron microscopy we found that the co-aggregation of Aβ and ferritin resulted in the conversion of ferritin’s inert ferric core into more reactive low-oxidation-states. Such findings strongly implicate Aβ in the altered iron handling and increased oxidative stress observed in AD pathogenesis. These amyloid-associated iron phases have biomarker potential to assist with disease diagnosis and staging, and may act as targets for therapies designed to lower oxidative stress in AD tissue.
nature.com